ARCT Q4 2025 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-65.7% YoY

Gross Profit

$29M408.3% margin

Operating Income

-$31M-435.0% margin

Net Income

$47M650.3% margin

EPS (Diluted)

$-1.05

QoQ Revenue Growth

-58.0%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$271M

Total Liabilities

$57M

Stockholders' Equity

$214M

Cash & Equivalents

$231M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$21M	-65.7%
Gross Profit	$29M	$21M	+39.9%
Operating Income	-$31M	-$33M	+6.3%
Net Income	$47M	-$30M	+256.0%

Revenue Segments

Grant

$4M57%

Collaboration Revenue

$3M43%